Table 3.

Liquid biopsy applications currently in use or near use in Nordic clinical practice.

Clinical Status	Liquid Biopsy Test	Method	Clinical Application	References
Currently in use	cfDNA EGFR gene mutation testing	Quantitative PCR	Predictive for EGFR-directed treatment (TKI inhibitors) of advanced lung cancer	[71,72,73,74,115,117,118]
Food and Drug Ad-ministration (FDA) approved	FoundationOne Liquid CDx multigene panel (incl. EGFR, ALK, PIK3CA, BRCA genes)	Targeted sequencing	Predictive for targeted treatment of metastatic lung, prostate and breast cancer	[119,120,121]
FDA approved	cfDNA KRAS and NRAS gene mutation testing	BEAMing, Digital PCR	Predictive for EGFR-directed treatment of metastatic colorectal cancer	[75]
FDA approved	cfDNA TMB testing	Targeted sequencing	Predictive for treatment of several solid cancers with immune checkpoint inhibitors	[90,91]
FDA approved	AR-V7 splice variant testing in CTCs	Immunofluorescence	Treatment choices for metastatic castration-resistant prostate cancer	[79,80]
FDA approved	CellSearch CTC enumeration	Immuno- logical enrichment/ staining	Prognostic stratification of breast, prostate and colorectal cancer	[58,60]